Eli Lilly Lifts Revenue Outlook as Volume Surge Outpaces Price Erosion

Eli Lilly delivered a quarter that was stronger at the top line than beneath it, and investors chose to focus on the former. Shares of the Indianapolis drugmaker rose 5.7% today after the company raised its full-year revenue guidance, even as acquisition-related research costs dragged its adjusted profit forecast lower.

Revenue for the third quarter of 2026 climbed 39% year over year to $24.4 billion. The gain was powered almost entirely by volume, which jumped 53%, while realized prices fell 15% worldwide — a 7% decline in the United States and a steeper 29% drop abroad. Lilly is simply selling far more medicine at lower prices, and that distinction matters for anyone trying to judge how much of the growth is repeatable.

One-Time Tailwinds Inflate the Top Line

Roughly $900 million of the quarterly revenue came from positive one-off effects, according to Reuters, including $410 million in milestone payments tied to Jardiance. Management does not expect further payments of that kind. Strip those out and the underlying demand story still looks robust — but the headline number overstates the recurring momentum.

The two metabolic blockbusters continue to do the heavy lifting. Mounjaro generated $10.72 billion worldwide, up 65% from the year-earlier period, while Zepbound contributed $5.35 billion. Not every product kept pace: Foundayo posted $184 million in quarterly sales, short of the $216.86 million analysts had modeled.

Guidance Split Has a Mechanical Explanation

For the full year, Lilly now projects revenue of $91–92 billion, up from a prior range of $85–87 billion. Adjusted earnings, by contrast, are guided to $35–36 per share, down from $35.50–36.50.

The two moves are not in conflict. Acquired research and development costs — stemming chiefly from the AtaiBeckley and Curevo takeovers, per Reuters — are weighing on the profit outlook to the tune of $4.57 per share. Meanwhile, the underlying earnings forecast improved by $4.07 per share at the midpoint. The acquisitions simply cost more than that improvement could offset.

That same charge was already embedded in the third quarter, yet adjusted earnings still came in at $7.48 per share — 7% above the prior-year figure and comfortably ahead of the $6.26 Reuters-cited consensus.

A Wider Patient Funnel

Broader access to obesity treatments is adding a fresh leg of growth. A Medicare pilot that began in July gave 500,000 patients access to these therapies, and 80% of them had never been treated with an incretin before — a sign of genuine market expansion rather than switching between existing drugs. CEO David Ricks called the speed of that rollout unprecedented, while acknowledging it makes forecasting harder.

Further out, Lilly plans to file for FDA approval of retatrutide in the first quarter of next year. J.P. Morgan analysts, cited by Reuters, see additional upside, particularly outside the United States.

The takeaway for shareholders: the underlying business is improving, the raised revenue range reflects confidence in demand rather than pricing power, and the trimmed profit guidance is an accounting consequence of dealmaking — not a warning about the franchise.